Gilead Sciences GILD
NASDAQ GILD
$144.80 -0.85 (-0.58%)
As of: Sep 10, 2026 · 3:59 PM EDT

Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026)

Gilead Sciences' (GILD) quarterly Other Non-Current Assets came in at $4.8 billion in Q2 2026, up 17.86% on a YoY basis from $4.0 billion in Q2 2025, and up 4.33% quarter-over-quarter from $4.6 billion in Q1 2026.

Analysis

Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026) Analysis & Trends

Gilead Sciences (GILD) has reported Other Non-Current Assets for 18 consecutive years, with $4.8 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Non-Current Assets rose 17.86% year-over-year to $4.8 billion; the trailing twelve-month figure through Jun 2026 stood at $4.8 billion (up 17.86% YoY), and the FY2025 full-year result was $4.8 billion, up 28.55% from the prior year.
  • Other Non-Current Assets improved to $4.8 billion in Q2 2026 per GILD's latest filing, from $4.6 billion in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.5 billion in Q3 2024 and bottomed at $3.8 billion in Q4 2024.
  • Historically, Other Non-Current Assets has averaged $4.7 billion across 5 years, with a median of $4.8 billion in 2022.
  • The sharpest annual moves came in 2024 and 2025: Other Non-Current Assets soared 30.81% in 2024, then retreated 25.39% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $4.8 billion in 2022, then fell by 0.17% to $4.8 billion in 2023, then fell by 21.35% to $3.8 billion in 2024, then increased by 28.55% to $4.8 billion in 2025, then dropped by 1.94% to $4.8 billion in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods registered $4.8 billion, $4.6 billion, and $4.8 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 12.98 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 4.75 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 1.25 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 2.31 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 124.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 618.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 65.13 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 831.80 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 29.59 Mn
10 Insmed 27.67 Bn 26.51 Bn 358.27 Mn 104.44 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 4.75 Bn
Mar 31, 2026 4.55 Bn
Dec 31, 2025 4.85 Bn
Sep 30, 2025 4.87 Bn
Jun 30, 2025 4.03 Bn
Mar 31, 2025 3.87 Bn
Dec 31, 2024 3.77 Bn
Sep 30, 2024 5.49 Bn
Jun 30, 2024 4.77 Bn
Mar 31, 2024 5.19 Bn
Dec 31, 2023 4.79 Bn
Sep 30, 2023 4.20 Bn
Jun 30, 2023 5.11 Bn
Mar 31, 2023 4.95 Bn
Dec 31, 2022 4.80 Bn
Sep 30, 2022 4.62 Bn
Jun 30, 2022 4.86 Bn
Mar 31, 2022 5.13 Bn
Dec 31, 2021 4.96 Bn
Sep 30, 2021 4.74 Bn